Table 1.
Demographic and baseline characteristics of participants by long-term all-cause mortality
| No events (n = 9,253) | Events (n = 239) | P value | |
|---|---|---|---|
| Age (years) | 46.00 (31.00–61.00) | 73.00 (62.00–80.00) | < 0.001 |
| Age group | |||
| < 65 years | 7533 (81.41%) | 74 (30.96%) | < 0.001 |
| ≥ 65 years | 1720 (18.59%) | 165 (69.04%) | |
| Sex | |||
| Male | 4437 (47.95%) | 148 (61.92%) | < 0.001 |
| Female | 4816 (52.05%) | 91 (38.08%) | |
| Race | |||
| Mexican American | 1575 (17.02%) | 40 (16.74%) | < 0.001 |
| Non-Hispanic white | 1093 (11.81%) | 21 (8.79%) | |
| Non-Hispanic black | 2844 (30.74%) | 107 (44.77%) | |
| Other Hispanic | 2045 (22.10%) | 50 (20.92%) | |
| Other races | 1696 (18.33%) | 21 (8.79%) | |
| Drinking | 4392 (47.47%) | 81 (33.89%) | < 0.001 |
| Smoking | 3598 (38.88%) | 149 (62.34%) | < 0.001 |
| Hypertension | 3055 (33.02%) | 147 (61.51%) | < 0.001 |
| Diabetes | 1252 (13.53%) | 80 (33.47%) | < 0.001 |
| Heart failure | 237 (2.56%) | 49 (20.50%) | < 0.001 |
| CAD | 291 (3.14%) | 40 (16.74%) | < 0.001 |
| Stroke | 301 (3.25%) | 35 (14.64%) | < 0.001 |
| Lipid-lowering drugs | 1597 (17.26%) | 89 (37.24%) | < 0.001 |
| BMI (kg/m2) | 28.40 (24.50–33.40) | 28.55 (24.60–32.20) | 0.629 |
| Hs-CRP (mg/L) | 1.88 (0.80–4.43) | 3.01 (1.30–6.59) | < 0.001 |
| HDL-C (mmol/L) | 1.32 (1.09–1.60) | 1.29 (1.03–1.58) | 0.144 |
| HDL-C (mg/L) | 5.10 (4.22–6.19) | 4.99 (3.98–6.11) | |
| Hs-CRP/HDL-C ratio | 0.37 (0.14–0.94) | 0.56 (0.24–1.38) | < 0.001 |
Data were presented as median (Q1-Q3) or N (%). CAD, coronary artery disease; BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; Divide HDL-C (mmol/L) by 0.2586 to convert to mg/L